Drug-like compounds are most of the time denied approval and use owing to the unexpected clinical side effects and cross-reactivity observed during clinical trials. These unexpected outcomes resulting in significant increase in attrition rate centralizes on the selected drug targets. These targets m...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!